Package Leaflet: Information for the User
Rapamune 1 mg/ml Oral Solution
sirolimus
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
|
Contents of the pack
Rapamune contains the active substance sirolimus, which belongs to a group of medicines called immunosuppressants. It helps to control your body's immune system after you have received a kidney transplant.
Rapamune is used in adults to prevent rejection of transplanted kidneys and is normally used in combination with other immunosuppressive medicines called corticosteroids, and initially (for the first 2 to 3 months) with cyclosporin.
Rapamune is also used to treat patients with sporadic lymphangioleiomyomatosis (S-LAM) with moderate to severe lung disease or declining lung function. S-LAM is a rare, progressive lung disease that mainly affects women of childbearing age. The most common symptom of S-LAM is difficulty breathing.
Do not take Rapamune
Warnings and precautions
Tell your doctor or pharmacist before you start taking Rapamune.
Your doctor will do tests to monitor your blood levels of Rapamune. Your doctor will also do tests to check your kidney function, to measure your lipid (cholesterol and/or triglyceride) levels in your blood, and possibly your liver function, during treatment with Rapamune.
Exposure to sunlight and UV light should be limited by covering your skin with clothing and using a sunscreen with a high sun protection factor, due to the increased risk of skin cancer.
Children and adolescents
Experience with the use of Rapamune in children and adolescents under 18 years of age is limited. The use of Rapamune in this population is not recommended.
Taking Rapamune with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Some medicines may interfere with the action of Rapamune and may require a dose adjustment. In particular, you should tell your doctor or pharmacist if you are taking any of the following medicines:
Vaccines containing live organisms should be avoided during treatment with Rapamune. Before vaccination, tell your doctor or pharmacist that you are receiving Rapamune.
Treatment with Rapamune may lead to increased levels of cholesterol and triglycerides in your blood (blood fats) that may require treatment. Medicines known as "statins" and "fibrates" used to treat high cholesterol and triglycerides have been associated with an increased risk of muscle fibre breakdown (rhabdomyolysis). Tell your doctor if you are taking medicines to lower your blood fats.
The combined use of Rapamune and angiotensin-converting enzyme (ACE) inhibitors (a type of medicine used to lower blood pressure) may cause allergic reactions. Tell your doctor if you are taking these medicines.
Taking Rapamune with food and drink
Always take Rapamune the same way, with or without food. If you prefer to take Rapamune with food, you should always take it with food. If you prefer to take Rapamune without food, you should always take it without food. Food can affect the amount of medicine that gets into your blood and, therefore, taking your medicine the same way each time will help keep your blood levels of Rapamune more stable.
Do not take Rapamune with grapefruit juice.
Pregnancy, breastfeeding, and fertility
Rapamune should not be used during pregnancy unless clearly necessary. You should use effective contraception during treatment with Rapamune and for 12 weeks after stopping treatment. If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
It is not known whether Rapamune passes into breast milk. Patients who take Rapamune should not breastfeed.
A reduction in sperm count has been associated with the use of Rapamune, which usually returns to normal after stopping treatment.
Driving and using machines
Although treatment with Rapamune is not expected to affect your ability to drive, if you are unsure, consult your doctor.
Rapamune contains ethanol (alcohol)
Rapamune contains up to 3.17% ethanol (alcohol). An initial dose of 6 mg contains up to 150 mg of alcohol, which is equivalent to 3.80 ml of beer or 1.58 ml of wine. This amount of alcohol may be harmful for individuals with alcoholism, as well as for pregnant or breastfeeding women, children, and high-risk groups, such as patients with liver disease or epilepsy. Alcohol may modify or increase the effect of other medicines.
Maintenance doses of 4 mg or less contain small amounts of ethanol (100 mg or less), amounts that are probably too low to be harmful.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
Your doctor will decide the exact dose of Rapamune that you should take and how often you should take it. Always follow your doctor's instructions and never change the dose yourself.
Rapamune is for oral use only. Tell your doctor if you have difficulty taking the oral solution.
Always take Rapamune the same way, with or without food.
Kidney transplant
Your doctor will give you an initial dose of 6 mg as soon as possible after your kidney transplant operation. After this, you will need to take 2 mg of Rapamune every day until your doctor tells you otherwise. Your dose will be adjusted depending on your blood levels of Rapamune. Your doctor will need to do blood tests to measure the levels of Rapamune in your blood.
If you are also taking cyclosporin, you should take the two medicines approximately 4 hours apart.
It is recommended that you first take Rapamune in combination with cyclosporin and corticosteroids. After 3 months, your doctor may stop Rapamune or cyclosporin, as it is not recommended to take these medicines together after this time.
Sporadic lymphangioleiomyomatosis (S-LAM)
Your doctor will give you 2 mg of Rapamune per day, until further notice. Your dose will be adjusted according to your blood levels of Rapamune. Your doctor will need to do blood tests to measure the levels of Rapamune in your blood.
Instructions on how to dilute Rapamune
When refrigerated, the solution in the bottle may become slightly cloudy. If this happens, simply leave the Rapamune oral solution at room temperature and gently shake. The presence of this cloudiness does not affect the quality of Rapamune.
If you take more Rapamune than you should
If you have taken more medicine than you should, contact your doctor or go to the nearest hospital emergency department immediately. Always take the bottle and label with you, even if it is empty.
If you forget to take Rapamune
If you forget to take Rapamune, take it as soon as you remember, but not within 4 hours of your cyclosporin dose. After this, continue taking your medicine as usual. Do not take a double dose to make up for a forgotten dose, and always take Rapamune and cyclosporin with an interval of approximately 4 hours. If you have forgotten to take a dose of Rapamune, you should inform your doctor.
If you stop taking Rapamune
Do not stop taking Rapamune unless your doctor tells you to, as you may be at risk of losing your transplant.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Allergic Reactions
You should see yourdoctor immediatelyif you experience symptoms such as swelling of the face, tongue, and/or throat (angioedema) and/or difficulty breathing, or skin peeling (exfoliative dermatitis). These could be symptoms of a severe allergic reaction.
Kidney Damage withLow Blood Cell Counts (Thrombocytopenic Purpura/Hemolytic Uremic Syndrome)
When taken with medicines called calcineurin inhibitors (cyclosporine or tacrolimus), Rapamune may increase the risk of a condition that combines kidney damage with low blood cell counts, with or without skin irritation (thrombocytopenic purpura/hemolytic uremic syndrome). If you experience symptoms such as bruising, skin rash, changes in urine, mood changes, or any other symptom that you consider serious, unusual, or prolonged, contact your doctor.
Infections
Rapamune decreases your body's defense mechanisms. As a result, your body will not be as good at fighting infections. Therefore, if you are taking Rapamune, you may get more infections than usual, such as skin, mouth, stomach, and intestinal infections, lung and urinary tract infections (see list below). You should contact your doctor if you experience symptoms that you consider serious, unusual, or prolonged.
Frequency of Adverse Effects
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Frequency not known: cannot be estimated from available data
Patient with S-LAM experienced adverse effects similar to those of patients with kidney transplant, with the addition of weight loss, which may affect more than 1 in 10 people.
Reporting Adverse Effects
If you experience any adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging after "EXP". The expiration date is the last day of the month indicated.
Store in a refrigerator (between 2°C and 8°C).
Keep Rapamune oral solution in its original bottle to protect it from light.
Once the bottle is opened, the contents must be refrigerated and used within 30 days. If necessary, the bottle can be stored at room temperature up to 25°C for a short period, but no more than 24 hours.
Once the dosing syringe has been filled with Rapamune oral solution, it must be stored at room temperature, but not above 25°C, for a maximum of 24 hours.
Once the contents of the dosing syringe have been diluted with water or orange juice, the preparation must be consumed immediately.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of packaging and medicines that are no longer needed. This will help protect the environment.
Rapamune Composition
The active substance is sirolimus. Each ml of Rapamune oral solution contains 1 mg of sirolimus.
The other ingredients are:
Polysorbate 80 (E433) and Phosal 50 PG (phosphatidylcholine, propylene glycol [E1520], mono- and diglycerides, ethanol, soybean fatty acids, and ascorbyl palmitate).
This medicine contains approximately 350 mg of propylene glycol (E1520) per ml.
Product Appearance and Packaging Contents
Rapamune oral solution is a pale yellow to yellow oral solution presented in 60 ml bottles.
Each pack contains: 1 bottle (topaz glass) containing 60 ml of Rapamune solution, a syringe adapter, 30 dosing syringes (topaz plastic), and a carrying case for the syringe.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder: Pfizer Europe MA EEIG Boulevard de la Plaine 17 1050 Brussels Belgium | Manufacturer: Pfizer Service Company BV Hoge Wei 10 1930 Zaventem Belgium |
You can obtain more information about this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/BelgienLuxembourg/Luxemburg Pfizer NV/SA Tel/Tel: +32 (0)2 554 62 11 | Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel: +3705 2514000 |
България Пфайзер България ЕООД Тел: +359 2 970 4333 | Magyarország Pfizer Kft. Tel: +36 1 488 3700 |
Česká Republika Pfizer, spol. s r.o. Tel: +420 283 004 111 | Malta Vivian Corporation Ltd. Tel: +35621 344610 |
Danmark Pfizer ApS Tlf: +45 44 201 100 | Nederland Pfizer bv Tel: +31 (0)800 63 34 636 |
Deutschland Pfizer Pharma GmbH Tel: +49 (0)30 550055-51000 | Norge Pfizer AS Tlf: +47 67 52 61 00 |
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500 | Österreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0 |
Ελλάδα Πφайζερ Ελλάς Α.Ε. Τηλ.: +30 210 6785 800 | Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 00 |
España Pfizer, S.L. Tel:+34914909900 | Portugal Laboratórios Pfizer, Lda. Tel: +351 21 423 5500 |
France Pfizer Tél: +33 (0)1 58 07 34 40 | România Pfizer Romania S.R.L Tel: +40 (0)21 207 28 00 |
Hrvatska Pfizer Croatia d.o.o. Tel: + 385 1 3908 777 | Slovenija Pfizer Luxembourg SARL, Pfizer, podružnica za svetovanje s podrocja farmacevtske dejavnosti, Ljubljana Tel: +386 (0)1 52 11 400 |
Ireland Pfizer Healthcare Ireland Unlimited Company Tel: +1800 633 363 (toll free) Tel: +44 (0)1304 616161 | Slovenská Republika Pfizer Luxembourg SARL, organizacná zložka Tel: + 421 2 3355 5500 |
Ísland Icepharma hf Tel: +354 540 8000 | Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 040 |
Italia Pfizer S.r.l. Tel: +39 06 33 18 21 | Sverige Pfizer AB Tel: +46 (0)8 550 520 00 |
Κύπρος Πφайζερ Ελλάς Α.Ε. (Κύπρος) Τηλ.: +357 22 817690 | |
Latvija Pfizer Luxembourg SARL filiale Latvija Tel. +371 67035775 |
Date of Last Revision of this Leaflet: 01/2025.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/